If this message does not appear correctly, click this link

Breakthroughs at ASCO 2019 –The First KRAS Inhibitor And Progress In Established Drug Targets?

By Dr. Nina Lapke, Biomedical Informatics Scientist of ACT Genomics

A presumed undruggable cancer driver, KRAS, can be inhibited finally. Also, treatment progress in METex14 mutations improves outcomes in lung cancer, while HER2-specific antibody, margetuximab, is Fc-engineered to achieve higher drug efficacy.

Find Out More Insights

ACT Genomics Collaborates with AIA Hong Kong to Promote Precision Cancer Medicine

Image title

ACT Genomics is excited to collaborate with AIA Hong Kong to bring ACT Genomics’ leading cancer profiling service to AIA Hong Kong customers. The aim is to take medical insurance cover to a new level by assisting customers to utilize their financial resources more efficiently in obtaining optimal medical treatment. 

Find Out More

ACT Genomics Wins Taiwan Bio Industry Organization Awards- Emerging Company of the Year 

Image title

ACT Genomics drives innovation in global standard and individual markets, winning Taiwan Bio Industry Organization Awards- Emerging Company of the Year, and also its flagship service ACTOnco®+ wins the gold award of 2019 Taipei Biotechnology Award with 1 million grants from Taipei City Government.

2019 Taiwan Bio Industry Organization Awards- Emerging Company of the Year

2019 Taipei Biotechnology Award

ACT Genomics Published Three Cancer Precision Medicine Studies On International Journals

To understand whether maintenance chemotherapy could improve progression-free survival (PFS) in stages III/IV ovarian cancer, a post hoc translational study was conducted to deep sequence BRCA/homologous recombination deficiency (HRD) genes for better prognosis. ACT Genomics found out Wild-type BRCA/non-HRD subgroup seemed to fare better with maintenance therapy1;For mCRC patients, ACT Genomics found that TP53 DBD missense mutations may predict prolonged PFS in mCRC patients treated with bevacizumab-based therapy.2; In the hope of discovering predictive biomarkers towards EGFR-TKI treatment, advanced EGFR mutant NSCLC patients who underwent treatment with first generation TKIs were studied and ACT Genomics found that FGFR3 mutation and CDKN2A CNV loss may be potential predictive markers for treatment outcome and warrant further investigation3.

1 The study is published on J Gynecol Oncol : Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group 

2 The study is published on Cancers : TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer

3 The study is published on Translational Oncology : Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors

More ACT Genomics Publications on International Journals

BLU-667 demonstrates the antitumor activity in RET fusion-positive NSCLC and other cancers

RET rearrangements have been found to promote cell proliferation in cancer, and a phase I study showed BLU-667 has antitumor activity in patients with RET fusion-positive tumor.

Learn More

TAK-788 Shows Clinical Benefit in NSCLC Patients with EGFR Exon 20 Insertions

No currently approved drug can target the EGFR exon 20 insertions in NSCLC, and TAK-788 is a potential treatment for these type of patients.

Learn More

Olaparib shows efficacy in castration-resistant prostate cancer with defects in DNA-repair genes

The PARP inhibitor olaparib demonstrates antitumor activity in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair gene defects.

Learn More

Please do not reply to this email as it is sent from a non-monitored account. To contact us, please email service@actgenomics.com.

  To unsubscribe, please enter your E-Mail :